Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
Hispanics have higher MM-related in-hospital mortality; recent decline seen in in-hospital mortality for all except NH-Blacks.
Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
Researchers sought to assess the disease-specific costs for Medicare recipients with multiple myeloma.
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
A single-center study found anti-COVID-19 protection lowest in patients with MM at 2 weeks after their second BNT162b2 mRNA shot than did patients with myeloproliferative malignancies, and was highest in older patients without cancer.
Researchers sought to determine the real-world renal function and outcomes for patients with multiple myeloma according to type of treatment and line of therapy.
Researchers sought to determine whether poorer health-related quality of life would be linked to responses about pain severity in patients with multiple myeloma.
The approval was based on data from the phase 3 APOLLO trial.
Considerable variation seen in magnitude of antibody response, from 5 to 7,882 AU/mL, following two doses of mRNA COVID-19 vaccine.
The results point to patients who might benefit from early intervention.
Adding isatuximab to carfilzomib and dexamethasone improved outcomes.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
A progression-free survival benefit did not translate to overall survival.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Researchers sought to determine if knowing treatment assignment would lead to patient bias among participants in multiple myeloma clinical trials.
Overall survival data were not mature.
Younger patients had a significant decrease in sleep time on days they received dexamethasone.